Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHBQYU)

• Drug Name: CAR-T cells targeting CD138 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Clinical trial	[1]

• Cross-matching ID: TTD Drug ID: DMHBQYU

Molecule-Related Drug Atlas

Drug(s) Targeting Syndecan-1 (SDC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BT-062	DMYO185	Multiple myeloma	2A83	Phase 2	[2]
CD138 CAR T cells	DMCSGNU	Multiple myeloma	2A83	Phase 1/2	[3]
CART-138 cells	DMB4HEW	Multiple myeloma	2A83	Phase 1/2	[4]
CART-138 cells	DMB4HEW	Multiple myeloma	2A83	Phase 1/2	[5]
CAR138 T Cells	DMA9M81	Immune System disease	4A01-4B41	Phase 1	[6]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Syndecan-1 (SDC1)	TTYDSVG	SDC1_HUMAN	CAR-T-Cell-Therapy	[1]

References

• [1] ClinicalTrials.gov (NCT03473496) CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma
• [2] The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res. 2009 Jun 15;15(12):4028-37.
• [3] ClinicalTrials.gov (NCT03271632) Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
• [4] ClinicalTrials.gov (NCT01886976) Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138
• [5] ClinicalTrials.gov (NCT03196414) Study of CART-138/BCMA Therapy for R/R Multiple Myeloma
• [6] ClinicalTrials.gov (NCT03672318) Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma